Cardioprotective effects of neuropeptide galanin: Focusing on its roles against diabetic heart.

Yuqing She, Ran Ge, Xuewen Gu, Penghua Fang, Zhenwen Zhang

Peptides 2023 Jan

filter terms:

Following an unprecedented rise in the number of the aged, the incidence of age-related diseases, such as diabetes and cardiovascular disease, is consequently increasing in the world. Type 2 diabetes mellitus (T2DM) is associated with excess cardiovascular morbidity and mortality. The diabetic heart is characterized by increased cardiomyocyte stiffness and fibrotic changes. Despite many factors resulting in cardiomyocyte injury and dysfunction in diabetes, insulin resistance is still a critical etiology of diabetic cardiomyopathy. Preclinical and clinical studies have revealed an intriguing role for galanin in the pathogenesis of insulin resistance and diabetic heart disease. A significant change in plasma galanin levels occurred in patients suffering from type 2 diabetes or cardiomyocyte injury. In turn, galanin may also distinctly mitigate hyperglycemia and insulin resistance in diabetes as well as increase glucose metabolism and mitochondrial biogenesis in cardiac muscle. Here, we critically review current data about the multivariate relationship among galanin, insulin resistance, and cardiac muscle to comprehensively evaluate the protective role of galanin and its receptors for the diabetic heart and to determine whether galanin receptor 2 agonists potentially represent a feasible way to treat diabetic cardiomyopathy in the future. Copyright © 2022 Elsevier Inc. All rights reserved.

Citation

Yuqing She, Ran Ge, Xuewen Gu, Penghua Fang, Zhenwen Zhang. Cardioprotective effects of neuropeptide galanin: Focusing on its roles against diabetic heart. Peptides. 2023 Jan;159:170918